Drug intelligence / Profile preview

PRI-500

Development stage: Unknown
Lead developer: Priavoid
Modality: Peptides

Overview

PRI-500 is a synthetic peptide developed by Priavoid GmbH. It acts as a prion protein inhibitor (PRNP inhibitor), targeting the prion protein. The drug is currently in the discovery phase and is not yet approved for any specific indications.

Other names: PRI-500PRI500PRI 500

Targets

PrPSc (Major prion protein)

Beyond the preview

Go deeper on PRI-500.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRI-500.

Explore the full profile